NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free AKBA Stock Alerts $1.89 +0.19 (+11.18%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.70▼$2.0550-Day Range$1.35▼$1.8952-Week Range$0.49▼$2.05Volume9.65 million shsAverage Volume2.66 million shsMarket Capitalization$375.88 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Akebia Therapeutics alerts: Email Address Akebia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside138.1% Upside$4.50 Price TargetShort InterestBearish4.08% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.66Based on 18 Articles This WeekInsider TradingSelling Shares$300,598 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.28) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector253rd out of 947 stocksPharmaceutical Preparations Industry114th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Akebia Therapeutics has a forecasted upside of 138.1% from its current price of $1.89.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.08% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 1.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 2.0 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,598.00 in company stock.Percentage Held by InsidersOnly 3.84% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.04% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 63.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Akebia Therapeutics Stock (NASDAQ:AKBA)Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded to "Buy" at StockNews.comMarch 19, 2024 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC WainwrightMarch 19, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 19, 2024 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) & Karuna Therapeutics (NASDAQ:KRTX) Head-To-Head ContrastMarch 17, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33March 16, 2024 | finance.yahoo.comAkebia Therapeutics Full Year 2023 Earnings: EPS Beats ExpectationsMarch 15, 2024 | markets.businessinsider.comBuy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial PositionMarch 15, 2024 | finance.yahoo.comUS Life & Non-Life Insurance Market Poised for Strong Growth: In-Depth Analysis UnveiledMarch 19, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 14, 2024 | investorplace.comAKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023March 14, 2024 | benzinga.comRecap: Akebia Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comAkebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable QuarterMarch 14, 2024 | prnewswire.comAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 14, 2024 | markets.businessinsider.comAkebia Therapeutics earnings: here's what Wall Street expectsMarch 13, 2024 | benzinga.comEarnings Preview For Akebia TherapeuticsMarch 11, 2024 | finance.yahoo.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | prnewswire.comAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 1, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 22, 2024 | benzinga.comAkebia Therapeutics Stock (NASDAQ:AKBA), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comAKBA Mar 2024 1.500 putFebruary 2, 2024 | finance.yahoo.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA)January 31, 2024 | msn.comAkebia Therapeutics Secures $55M Credit Facility with Kreos CapitalJanuary 31, 2024 | markets.businessinsider.comOptimistic Buy Rating for Akebia Therapeutics Amid Strategic Financial Restructuring and Anticipated FDA ApprovalJanuary 30, 2024 | barrons.comAkebia Therapeutics Inc.January 30, 2024 | seekingalpha.comAkebia Therapeutics closes up to $55M loan facilityJanuary 30, 2024 | finance.yahoo.comAkebia Secures $55 Million Term Loan FinancingSee More Headlines Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees204Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+138.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,230,000.00 Net Margins-26.32% Pretax Margin-30.47% Return on EquityN/A Return on Assets-20.09% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.14 Sales & Book Value Annual Sales$194.62 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book63.00Miscellaneous Outstanding Shares198,880,000Free Float191,238,000Market Cap$375.88 million OptionableOptionable Beta0.78 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. John P. Butler MBA (Age 60)CEO, President & Director Comp: $1.29MMr. Michel Dahan (Age 45)Senior VP & COO Comp: $734.73kMs. Nicole R. Hadas J.D. (Age 51)Senior VP, Chief Legal Officer & Secretary Comp: $687.38kDr. Steven Keith Burke (Age 63)Senior VP of Research & Development and Chief Medical Officer Comp: $766.57kMs. Ellen E. Snow CPA (Age 51)CGMA, Senior VP, CFO & Treasurer Mr. Richard C. Malabre (Age 63)Chief Accounting Officer Ms. Kimberly GarkoSenior VP & Chief Technical OfficerTracey VetterickVice President of Portfolio Strategy & Corporate AdministrationMercedes CarrascoDirector of Corporate CommunicationsMr. Douglas Jermasek M.B.A. (Age 63)Vice President of Marketing & Strategy More ExecutivesKey CompetitorsWerewolf TherapeuticsNASDAQ:HOWLFoghorn TherapeuticsNASDAQ:FHTXRAPT TherapeuticsNASDAQ:RAPTVerastemNASDAQ:VSTMXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 86,155 shares on 3/11/2024Ownership: 3.825%Goldman Sachs Group Inc.Bought 71,201 shares on 3/1/2024Ownership: 0.036%John P ButlerSold 46,570 sharesTotal: $73,580.60 ($1.58/share)Michel DahanSold 8,661 sharesTotal: $13,684.38 ($1.58/share)Nicole R HadasSold 5,974 sharesTotal: $9,438.92 ($1.58/share)View All Insider TransactionsView All Institutional Transactions AKBA Stock Analysis - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price target for 2024? 3 equities research analysts have issued 1 year target prices for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2024? Akebia Therapeutics' stock was trading at $1.24 at the start of the year. Since then, AKBA shares have increased by 52.4% and is now trading at $1.89. View the best growth stocks for 2024 here. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company earned $56.20 million during the quarter, compared to the consensus estimate of $55.64 million. During the same quarter last year, the business posted ($0.04) EPS. What ETF holds Akebia Therapeutics' stock? Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.83%), Vanguard Group Inc. (3.83%), Federated Hermes Inc. (0.46%), Northern Trust Corp (0.16%), Sapient Capital LLC (0.11%) and Sapient Capital LLC (0.10%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKBA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.